To Compare the Effects of Terminalia Arjuna with Rosuvastatin on Total Cholesterol and Low Density Lipoprotein Cholesterol


Ved Prakash
Vijay kumar Sehgal
Vijay Kumar Bajaj
Harcharan Singh


Background:In India, CVD is a leading cause of death. Among the modifiable risk factors, hyperlipidemia is one of the important factors. Therefore lowering cholesterol level is a key factor in controlling this disease.Objectives: To compare the effect of Terminalia arjuna, an indigenous drug with Rosuvastatin on serum total cholesterol and low density lipoprotein cholesterol levels, in patients of either sex with dyslipidemia.Material and Methods: An open prospective randomized controlled study was conducted in on 60 patients for the duration of 12 weeks. Patients were distributed into two groups of 30 patients each. Group I was given Rosuvastatin 10 mg daily and group II was given capsules containing bark powder of T.arjuna 500 mg twice daily. Patients TC and LDL-C levels were performed at baseline and then repeated at 4 weeks, 8 weeks and 12 weeks. The results of both the therapies were then compared and statistically analyzed.Results: T.arjuna leads to greater reduction in mean TC level than Rosuvastatin (-14.06±8.07% vs -10.10±5.39%), (- 24.73±10.69% vs -19.42±9.98%) and (-27.89±9.25% vs - 24.74±10.02%) at 4, 8 and 12 weeks respectively. The difference between both the groups was statistically non-significant (p>0.05) at 4, 8 and 12 weeks. The reduction in mean LDL-C level was also greater with T.arjuna as compared to Rosuvastatin.Conclusion: Both Rosuvastatin and T.arjuna were effective in causing significant decrease in serum TC and LDLC levels, but T.arjuna had a slight edge over Rosuvastatin as it showed greater reduction in TC and LDL-C levels as compare to Rosuvastatin. And was found to be safe and well tolerated.


How to Cite
Prakash, V., Sehgal, V. kumar, Bajaj, V. K., & Singh, H. (2016). To Compare the Effects of Terminalia Arjuna with Rosuvastatin on Total Cholesterol and Low Density Lipoprotein Cholesterol. International Journal of Medical and Dental Sciences, 1056–1066.


  1. Medicinenet.Com.Healthcareblog[Internet ].[Cited2015Aug28].Availablefrom: /art.asp?articlekey=33979.
  2. Malloy MJ, Kane JP. Agents used in dyslipidemia. In: Katzung GB, Masters SB, Trevor AJ, editors. Basic and clinical pharmacology. 12th ed. New York: McGraw Hill Companies; 2012.p.619-34.
  3. Libby P. The pathogenesis, prevention, and treatment of atherosclerosis. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s principle of internal medicine. 18th ed. New Delhi and New York: Tata McGraw Hill Companies; 2012.p.1983-91.
  4. Berglund L, Sacks F, Brunzell JD. Risk factors for cardiovascular disease. Renewed interest in triglycerides. Clin Lipidol 2013;8(1):1-4.
  5. Fuster V, Kelly BB. In: Promoting cardiovascular health in the developing world: A critical challenge to achieve global health. Institute of medicine (IOM) committee on preventing the global epidemic of cardiovascular disease. Washington, DC: The National academies press. 2010;1-18.
  6. Pramanik S, Das AK, Chakrabarty M, Bandyopadhyay SK, Ghosh M, Dalai CK. Efficacy of alternate-day versus everyday dosing of atorvastatin. Indian J Pharmacol 2012;44(3):362–5.
  7. Gupta R, Misra A, Pais P, Rastogi P, Gupta VP. Correlation of regional cardiovascular disease mortality in India with lifestyle and nutritional factors. Int J Cardiol 2006;108(3):291-300.
  8. Antman ME, Selwyn PA, Loscalzo J. Ischemic heart disease. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s principle of internal medicine. 18th ed. New York: McGraw Hill Companies; 2012.p.19982014.
  9. Scheon JF. The heart. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins and Cotran’s pathologic basis of diseases. 8th ed. New Delhi: Elsevier Publication; 2010.p.529-86.
  10. Brown AL, Goldberg AC, Henderson KE, Lavine K, Kates A, Mistry NF. Preventive cardiology ischemic heart disease. In: Foster C, Mistry NF, Peddi PF, Sharma S, editors. The Washington manual of medical therapeutics. 33rd ed. New York and New Delhi: Lippincott William and Wilkins and Wolters Kluwer publication; 2010.p.65-154.
  11. Park K. Epidemiology of chronic noncommunicable diseases and conditions. In: Park’s text book of preventive and social medicine. 22th ed. Jabalpur: Banarasidas bhanot publication; 2013.p.338-43.
  12. Gaziano AT, Gaziano MJ. Epidemology of coronary vascular disease. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s principle of internal medicine. 18th ed. New York: McGraw Hill Companies; 2012.p.1811-6.
  13. Gaddam V, Li DY, Mehta JL. Antithrombotic effects of atorvastatin--an effect unrelated to lipid lowering. J Cardiovas Pharmacol Ther 2002;7(4):24753.
  14. Puel J. Statins and unstable angina: MIRACL. Ann Endocrinol (Paris) 2001;62(1 Pt 2):145-8.
  15. Sharma S, Sharma D, Agarwal N. Diminishing effect of arjuna tree (Terminalia arjuna) bark on the lipid and oxidative stress status of high fat high cholesterol fed rats and development of certain dietary recipes containing the tree bark for human consumption. Res in pharmacy 2012;2(4):22-30.
  16. Reddy DBS, Kumar PR, Bharavi K, Venkateswarlu U. Hypolipidemic activity of methanolic extract of terminalia arjuna leaves in hyperlipidemic rat models. Res J Med Sci 2011;5(3):172-5.
  17. Kaur N, Shafiq N, Negi H, Pandey A, Reddy S, Kaur H et al. Terminalia arjuna in chronic stable angina: Systematic review and meta-analysis. Cardiol Res and practice 2014.
  18. Maulik SK, Katiyar CK. Terminalia arjuna in cardiovascular Diseases: Making the transition from traditional to modern medicine in India. Current pharmaceutical biotechnology 2010;10(8).
  19. Gupta R, Singhal S, Goyle A, Sharma VN. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: A randomised placebo-controlled trial. J Assoc Physician India 2001;49:2315.
  20. Kumar S, Enjamoori R, Jaiswal A, Ray R, Seth S, Maulik SK. Catecholamineinduced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb). J Pharm pharmacol 2009;61(11):1529-36.
  21. Subramaniam S, Subramaniam R, Rajapandian S, Uthrapathi S, Gnanamanickam VR, Dubey GP. Antiatherogenic activity of ethanolic fraction of Terminalia arjuna bark on hypercholesterolemic rabbits. Evidencebased Compl and Alt Med 2009; 2011.
  22. Subramaniam S, Ramachandran S, Uthrapathi S, Gnamanickam VR, Dubey GP. Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia arjuna (Roxb) bark against PX-407 induced hyperlipidema. Indian J Exp Biol 2011;49(4):282-8.
  23. Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery disease. Indian heart J 1997;49(5):507-10.
  24. Jassal B, Kumar B, Bajaj V, Walia R. Cardiodepressant activity of 90% alcoholic extract of Terminalia arjuna and its probable mechanism of action. IJMDS 2013;2(2):144-52.
  25. Khaliq F, Parveen A, Singh S, Gondal R, Hussain ME, Fahim M. Improvement in myocardial function by Terminalia arjuna in streptozotocininduced diabetic rats: possible mechanisms. J Cardiovas Pharmacol Ther 2013;18(5):481-9.
  26. Kumar G, Srivastava A, Sharma SK, Gupta YK. Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study. Ayu 2012;33(2):197–201.
  27. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006;295(13):1556-65.

Most read articles by the same author(s)

1 2 > >>